High Frequency of Viridians Group Streptococci Bacteremia in Pediatric Neuroblastoma High-risk Patients During Induction Chemotherapy

Overview

Journal Sci Rep

Specialty Science

Date 2023 Apr 6

PMID 37024512

Authors

Ola El Kebbi

Cassandra S Prather

Lena Elmuti

Malak Khalifeh

Muayad Alali

Affiliations

Soon will be listed here.

Abstract

Existing literature on febrile neutropenia (FN) has categorized patients with acute leukemia or those undergoing allogeneic stem cell transplantation (SCT) as being high risk for severe infection, bacteremia, and poor outcomes. Comprehensive studies of infection risk in pediatric high-risk neuroblastoma (NB-HR) during induction chemotherapy are limited, and mostly merged within the solid tumor (ST) group. Therefore, it is unclear whether infectious complications and outcomes for NB-HR are the same as in other ST groups. We conducted a retrospective medical record review of pediatric FN patients in a single center from March 2009 to December 2016. FN episodes were categorized into five groups based on underlying diagnosis (acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), NB-HR during induction chemotherapy, other solid tumors, and SCT). Comparative analyses of infectious complications between patients with NB-HR and those with other types of cancer diagnoses were performed. A total of 667 FN episodes (FNEs) were identified in 230 patients. FNEs occurred in 82 episodes with NB-HR. Bloodstream infection (BSI) occurred in 145 (21.7%) of total FN episodes. The most isolated organisms were the viridians group streptococci (VGS) (25%). NB-HR patients have higher rates of VGS bacteremia (OR 0.15, 95% [CI 0.04, 0.56]) and are more likely to be admitted to the Pediatric Intensive Care Unit (PICU) compared to patients with other solid tumors (OR 0.36, 95% [CI 0.15, 0.84]). Interestingly, there is no difference in VGS rates between patients with NB-HR and those with AML despite the fact that NB-HR patients do not receive a cytosine arabinoside (AraC)-based regimen. This large neuroblastoma cohort showed that patients with NB-HR during induction chemotherapy are at higher risk for VGS bacteremia and PICU admissions compared with patients with other solid tumors. Further prospective studies are needed to investigate infection-related complications in this high-risk group and to improve morbidity and mortality.

Citing Articles

Clinical and microbiological profile of Viridans group streptococcal bacteraemia; experience from South India.

Arjun R, Niyas V, Hussain F, Surendran S, Mohan V Infez Med. 2024; 32(1):37-44.

PMID: 38456022 PMC: 10917554. DOI: 10.53854/liim-3201-5.

References

Okamoto Y, Ribeiro R, Srivastava D, Shenep J, Pui C, Razzouk B . Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003; 25(9):696-703. DOI: 10.1097/00043426-200309000-00005. View

Delebarre M, Dessein R, Lagree M, Mazingue F, Sudour-Bonnange H, Martinot A . Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor. J Infect. 2019; 79(2):95-100. DOI: 10.1016/j.jinf.2019.06.008. View

Moskalewicz R, Isenalumhe L, Luu C, Wee C, Nager A . Bacteremia in nonneutropenic pediatric oncology patients with central venous catheters in the ED. Am J Emerg Med. 2016; 35(1):20-24. DOI: 10.1016/j.ajem.2016.09.028. View

Curra M, Soares Junior L, Martins M, Santos P . Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein (Sao Paulo). 2018; 16(1):eRW4007. PMC: 5968807. DOI: 10.1590/s1679-45082018rw4007. View

Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View

Engelhard D, Elishoov H, Or R, Naparstek E, Nagler A, Strauss N . Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant. 1995; 16(4):565-70. View

Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M . Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021; 39(23):2552-2563. DOI: 10.1200/JCO.20.03144. View

Ramphal R . Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004; 39 Suppl 1:S25-31. DOI: 10.1086/383048. View

Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T . Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001; 37(6):537-42. DOI: 10.1002/mpo.1248. View

10.

Johannsen K, Handrup M, Lausen B, Schroder H, Hasle H . High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer. 2013; 60(7):1154-60. DOI: 10.1002/pbc.24448. View

11.

Martino R, Subira M, Manteiga R, Badell I, Argiles B, Sureda A . Viridans streptococcal bacteremia and viridans streptococcal shock syndrome in neutropenic patients: comparison between children and adults receiving chemotherapy or undergoing bone marrow transplantation. Clin Infect Dis. 1995; 20(2):476-7. DOI: 10.1093/clinids/20.2.476. View

12.

Whittle S, Smith V, Silverstein A, Parmeter M, Minard C, Bernhardt M . Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020; 67(10):e28417. PMC: 7722106. DOI: 10.1002/pbc.28417. View

13.

Rossetti F, Cesaro S, Putti M, Zanesco L . High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol. 1995; 12(4):387-92. DOI: 10.3109/08880019509029589. View

14.

Smith V, Foster J . High-Risk Neuroblastoma Treatment Review. Children (Basel). 2018; 5(9). PMC: 6162495. DOI: 10.3390/children5090114. View

15.

Weisman S, Scoopo F, JOHNSON G, Altman A, Quinn J . Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol. 1990; 8(3):453-9. DOI: 10.1200/JCO.1990.8.3.453. View

16.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

17.

Castagnola E, Conte M, Parodi S, Papio F, Caviglia I, Haupt R . Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma. Pediatr Blood Cancer. 2006; 49(5):672-7. DOI: 10.1002/pbc.21070. View

18.

Almyroudis N, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small T . Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005; 7(1):11-7. DOI: 10.1111/j.1399-3062.2005.00088.x. View

19.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

20.

Elting L, Bodey G, Keefe B . Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992; 14(6):1201-7. DOI: 10.1093/clinids/14.6.1201. View